Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 350 Stomach Neoplasms 31 Neoplasm Metastasis 30 Breast Neoplasms, Male 25 Neoplasms 16 Inflammatory Breast Neoplasms 12 Brain Neoplasms 12 Carcinoma, Non-Small-Cell Lung 10 Esophageal Neoplasms 7 Prostatic Neoplasms 6 Pancreatic Neoplasms 6 Urinary Bladder Neoplasms 5 Rectal Neoplasms 5 Adenocarcinoma 5 Sarcoma 4 Lung Neoplasms 4 HER2-positive Breast Cancer 4 Endometrial Neoplasms 4 Colorectal Neoplasms 4 Colonic Neoplasms 4 Unspecified Adult Solid Tumor, Protocol Specific 3 Triple Negative Breast Neoplasms 3 Salivary Gland Neoplasms 3 Head and Neck Neoplasms 3 HER2 Positive Breast Cancer 3 Cardiotoxicity 3 Carcinoma, Renal Cell 3 Carcinoma, Ovarian Epithelial 3 Carcinoma, Hepatocellular 3 Carcinoma, Ductal, Breast 3

Interventions

Lapatinib 2 ribociclib 1 Trastuzumab 1 Paclitaxel 1 Letrozole 1 Goserelin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Osteitis Deformans × Trastuzumab × Clear all

NCT00553358 2021-09-21

Neo ALTTO

Novartis

Phase 3 Completed

455 enrolled 34 charts

Breast Neoplasms, Osteitis Deformans

Data powered by HemOnc (CC BY 4.0) Colophon ⚡